Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with macular edema with center involvement in at least one eye, including those with focal or diffuse DME, neovascular AMD, or RVO
The ETDRS letter score in the study eye must be 60 letters or worse (approximate Snellen equivalent of 20/63)
Vital signs as specified within the protocol
You may not be if
Proliferative diabetic retinopathy in the study eye, with the exception of tufts of neovascularization less than one disc area with no vitreous hemorrhage
Patient, with type 1 or type 2 diabetes who have a hemoglobin A1C \> or = 12% at screening
other ocular conditions as specified in the protocol